Search PubMed⌕ Search

Biomedical subjects

M Washizuka

Publications and source records attributed to M Washizuka.

34 records · Page 2Linked to original sources
PubMed1987

[Clinical analysis and treatment of carcinoma of the prostate with bone metastasis].

We carried out a clinical analysis of carcinoma of the prostate with bone metastasis in 141 cases of prostatic cancer treated between 1965 and 1984. Among these, there were 64 cases of stage D, 45.4% and 55 cases of bone metastasis at the first visit. Stage D cases were mainly treated with estrogen. Poorly differentiated adenocarcinoma was observed in 62% of the stage D cases. Elevated pretreatment levels of serum acid phosphatase in the cases of bone metastasis were found in 47.8-71.4% of patients with poorly differentiated adenocarcinoma. Elevated acid phosphatase levels were also normalized by estrogen administration in over 60% of cases, regardless of the degree of differentiation. Also, clinical efficacy of estrogen was observed in more than 80% of stage D cases with any degree of differentiation. The most frequent clinically observed metastatic site was bone. Pain-relieving effects of estrogen, radiation and ifosfamide were observed in 76.3%, 92.3% and 70%, of patients, respectively. The cause of death in stage D patients was mainly aggravation of metastatic lesions. The period for which estrogen was effective was 45 months on average in cases who died at stage D. The period from reactivation to death averaged 16 months, while the period from the beginning of treatment to death in cases unresponsive to estrogen was only 11 months on average.

Adenocarcinoma↗
PubMed1985

Successful treatment of yolk sac tumor of the lower abdominal wall with lymph node metastases.

We report a case of a primary yolk sac tumor of the lower abdominal wall with inguinal lymph node metastases. To our knowledge, this is the first documented case originating in the lower abdominal wall. Radical surgery was performed, followed by combination chemotherapy consisting of bleomycin, vinblastine and cis-platinum. The patient has been free of disease for more than 2 years.

Abdominal Muscles↗
PubMed1985

Malignant mixed mesodermal tumor of bladder occurring after radiotherapy for cervical cancer: report of a case.

A rare case of radiation-induced malignant mixed mesodermal tumor of the bladder is reported. A 78-year-old woman complained of hematuria, which originated from a polypoid tumor in the bladder 15 years after radiotherapy for squamous cell carcinoma of the uterine cervix. The bladder tumor recurred 9 months after resection and partial cystectomy then was performed. Histological findings revealed malignant mixed mesodermal tumor composed of carcinomatous and sarcomatous elements. The former element consisted mainly of transitional cell carcinoma with occasional foci of squamous metaplasia and glandular differentiation, while the latter consisted of spindle cell sarcoma showing partly cartilaginous and osseous differentiation. The histogenesis of malignant mixed mesodermal tumor of the bladder also is discussed.

Aged↗
PubMed1984

[Adjuvant chemotherapy following total cystectomy for invasive bladder cancer with bleomycin, vincristine and methotrexate].

Eleven patients with invasive bladder cancer were treated with combination chemotherapy consisting of bleomycin (5 mg, i.m., day 1-7), vincristine (1 mg/sq.m.i.v., day 8) and methotrexate (200-300 mg/sq.m.i.v. day 8). Chemotherapy was started about 4 weeks following total cystectomy and repeated every 2 or 3 weeks at least for one year. Five of the patients were free of disease at the mean follow-up time of 35.6 months, ranging from 21 to 50 month. The 3-year survival rate was 54.5%. Bone marrow suppression (36%), nausea and vomiting (55%) were observed, but they were not serious and well tolerated. These results suggest that this regimen could be used safely as an adjuvant chemotherapy following total cystectomy for patients with invasive bladder cancer. Further evaluation will be necessary.

Adult↗
PubMed1984

[Prostate cancer].

The incidence of prostate cancer has recently increased in Japan. Since Huggins demonstrated the dramatic effect of antiandrogenic treatment, patients with prostate cancer are widely treated by bilateral orchiectomy and high dose estrogen. As the incidence of cardiovascular disease has also gradually increased in patients of prostate cancer treated by estrogen in Japan, radiotherapy, radical prostatectomy, antiandrogen such as chlormadinone acetate, cyproterone acetate and anticancer chemotherapy are now sought and tested clinically. The authors have emphasized multidisciplinary treatment according to the stage of prostate cancer. In particular, early prostate cancer without metastasis should be radically treated with radiotherapy or prostatectomy.

Chlormadinone Acetate↗
PubMed1984

[Chemotherapy of metastatic urothelial carcinoma. cis-Diamminedichloroplatinum combination chemotherapy for patients with decreased renal function].

Cis-diamminedichloroplatinum (CDDP) combination chemotherapy has induced a high response rate in the treatment of metastatic urothelial carcinoma at our clinic. However, due to the risks of renal failure, renal function manifested by creatinine clearance (Ccr) of more than 50 ml/min is suggested to be the requirement for CDDP therapy. Unfortunately, some patients do not meet this requirement. Thus, the renal function of patients who were treated with our combination chemotherapy was evaluated and the method of CDDP administration was modified for these patients. Four patients with Ccr in the range of 38 approximately 49 ml/min were treated and 3 patients achieved objective response; complete response in 1 case and partial response in 2 cases. Transient decrease in Ccr and elevation of blood urea nitrogen and serum creatinine were observed but these changes were reversible in all but 1 of the 10 courses. The results indicate that CDDP can be administered with reasonable safety without sacrificing anti-tumor activity in patients with Ccr of less than 50 ml/min.

Adenocarcinoma↗
PubMed1983

In vivo staining test with methylene blue for bladder cancer.

An in vivo staining test with 0.2 per cent methylene blue was applied to 129 patients with bladder tumor and 16 patients with chronic cystitis within a 6-year interval. Although normal mucosa did not pick up the stain nonpapillary in situ and microinvasive carcinomas did so frequently. Moderate dysplasia was stained in about half of the patients. The intensity of the stain in papillary tumors was correlated with the histologic anaplasia (grade). Grade 1 tumors were stained poorly or unstained in 86 per cent of the tests, whereas grades 2 and 3 tumors picked up the stain in 74 and 96 per cent of the tests, respectively. Even a tiny tumor, if poorly differentiated, was identified easily by the blue stain. The histologic anaplasia of tumors could be assessed roughly according to the intensity of the stain. However, chronic cystitis occasionally took up the stain, especially in cases of marked inflammatory infiltrate a deep stain was recognized. To differentiate nonpapillary early cancer from chronic cystitis the addition of a cytologic examination may be necessary.

Biopsy↗
PubMed1983

[Combination chemotherapy with bleomycin, vincristine and methotrexate for stage I non-seminomatous germ cell testicular tumors].

Ten patients with Stage I non-seminomatous germ cell testicular tumors underwent orchiectomy and combination chemotherapy with bleomycin, vincristine and methotrexate with CF rescue (BOM) as an induction therapy followed by cyclophosphamide, vincristine and methotrexate as a maintenance therapy (COM). The results were as follows: BOM seemed to be effective as a further treatment for Stage I non-seminomatous germ cell testicular tumor patients. All 10 patients are alive and disease-free for a period from 1 year and 6 months to 5 years and 3 months (mean: 3 years and 9 months). The chemotherapy should be continued at least for a year, since relapse occurred in 2 of 4 patients who received only induction therapy. However, they completely responded to other chemotherapy regimens (BVP and BOAM ). BOM and COM therapy were scarcely toxic and no serious side effects were recognized. From the above results, it was considered that combination chemotherapy (BOM and COM) can be an alternative treatment to the conventional retroperitoneal node dissection and radiation therapy for Stage I non-seminomatous germ cell tumors.

Adult↗
PubMed1983

[Choreito and Shakuyakukanzoto: their effects on facilitating the voiding of stones in the urinary tract].

We treated 30 patients having 37 urinary calculi in all, with " Choreito " (5 g/day) and " Shakuyakukanzoto " (5 g/day) to study whether these medicines hastened spontaneous calculus excretion. Within 2 months, 91% of the small calculi (5 X 5 mm and smaller), and 33% of the medium-sized (6 X 10 mm and below) were excreted. These results were similar to those obtained with conventional conservative treatment, and suggest that this therapy will be useful.

Adult↗
PubMed1983

[Diagnosis and treatment of carcinoma of the prostate].

The incidence of carcinoma of the prostate has recently increased in Japan, but it is still considerably less frequent than in other countries. The highest incidence of carcinoma of the prostate occurs at around 70 years of age, and more than half of all cases are in stage C and D when detected in Japan. Antiandrogenic treatment is still widely used, but unfortunately, results are unsatisfactory in terms of control and survival rates. Other treatment modalities, for example, radical prostatectomy, radiotherapy or chemotherapy should be studied in order to improve the results. Although the results of patients with stage A and B are rather favorable, those of patients of advanced prostatic cancer are miserable. The reason is considered to be difficulty to cure large primary lesion and metastases. Development of treatment modality for stage C is therefore most important at present. In order to reduce size of primary lesion or metastatic pelvic lymph nodes estrogen should be given prior to operation or radiotherapy. Improvement of chemotherapy for the prostatic cancer will provide better results.

Adenocarcinoma↗
PubMed1983

[Primary multiple malignant tumors associated with bladder cancer].

Of 487 patients with urothelial bladder cancer seen during the past 22 years, 37 (7.6%) had other primary malignant tumors. In recent years the number of patients with double cancer markedly increased. The male/female ratio was 2.7:1 and the mean age at the time of diagnosis of the second primary cancer was 70 (56-84) years. Of the other organ cancers, 18 (47%) were in the digestive tract and 7 (18%) in the respiratory tract. Six patients had lesions that were diagnosed simultaneously and 31 had lesions that were diagnosed at intervals. The interval in 31 patients with metachronous double cancer ranged from 1 year and 1 month to 40 years; the mean interval was 9 years and 7 months.

Age Factors↗
PubMed1982

[Chemotherapy of metastatic urothelial carcinoma].

Six patients with metastatic urothelial carcinoma--4 transitional cell carcinomas and 2 adenocarcinomas--were treated with cis-platinum (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU). CDDP (12-15 mg/m2) and 5-FU (300 mg/m2) were given on day 1-5 and ADM (30 mg/m2) was given on day 1. Courses were repeated every 3-4 weeks. In 4 cases of transitional cell carcinoma, 1 complete remission and 3 partial remissions, were obtained, but in 2 cases of adenocarcinoma, only symptomatic improvement was observed. General toxic effects consisted of vomiting, alopecia, myelosuppression and disturbance of renal function, but the therapy was well tolerated. Our encouraging results to date seemed to indicate the higher degree of effectiveness of this combination chemotherapy against the chemoresistant disease.

Adenocarcinoma↗